8064804|t|Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
8064804|a|Four regioisomers of 2-amino-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine (2a-5a) were synthesized as the racemates to evaluate the utility of exocyclic amidines in the development of novel agonists for M1 muscarinic receptors. Of the four regioisomers, only racemic 2-amino-5-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine (4a; CDD-0075-A) displayed high affinity (IC50 = 10 +/- 3.0 microM) and activity at muscarinic receptors coupled to PI metabolism in the rat cortex (260 +/- 4.5% stimulation above basal levels at 100 microM). A series of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines then was synthesized for further evaluation as M1 agonists. Only the propargyl derivative (4d) retained substantial agonist activity (120 +/- 14% at 100 microM) in this series. On the basis of the activity of the 5-(alkoxycarbonyl)-1,4,5,6- tetrahydropyrimidines (1a and 1d) and the 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines, the corresponding cyclic guanidine derivatives were synthesized and tested. 2-Amino-5-(methoxycarbonyl)-1,4,5,6-tetrahydropyrimidine (7a) displayed a modest affinity for muscarinic receptors in the CNS (22 +/- 5.3 microM) and an ability to stimulate PI turnover in rat cerebral cortex (81 +/- 16% at 100 microM). The propargyl derivative (7d) also had modest binding affinity (31 +/- 15 microM) and high activity (150 +/- 8.5% at 100 microM), as expected based on the activity of propargyl esters of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine. Computational chemical studies revealed five distinct minimum-energy conformations for 1a, (R)-4a, and 7a, and three for 1d, (R)-4d, and 7d, each with a unique orientation of the ester moiety. Each of the five conformations for 1a could be superimposed upon a unique conformer of (R)-4a and 7a, suggesting that the compounds interact with muscarinic receptors in a similar fashion. Taken together, the data indicate the general utility of amidine systems as suitable replacements for the ammonium group of acetylcholine in developing ligands with activity at M1 muscarinic receptors in the central nervous system. Such compounds might be useful in the treatment of patients with Alzheimer's disease.
8064804	51	105	2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines	Chemical	-
8064804	110	166	2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines	Chemical	-
8064804	224	276	2-amino-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine	Chemical	-
8064804	278	283	2a-5a	Chemical	-
8064804	356	364	amidines	Chemical	MESH:D000578
8064804	470	524	2-amino-5-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine	Chemical	-
8064804	526	528	4a	Chemical	-
8064804	530	540	CDD-0075-A	Chemical	-
8064804	662	665	rat	Species	10116
8064804	746	800	2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines	Chemical	-
8064804	870	879	propargyl	Chemical	-
8064804	892	894	4d	Chemical	-
8064804	1014	1063	5-(alkoxycarbonyl)-1,4,5,6- tetrahydropyrimidines	Chemical	-
8064804	1065	1074	1a and 1d	Chemical	-
8064804	1084	1138	2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines	Chemical	-
8064804	1158	1174	cyclic guanidine	Chemical	-
8064804	1216	1272	2-Amino-5-(methoxycarbonyl)-1,4,5,6-tetrahydropyrimidine	Chemical	-
8064804	1274	1276	7a	Chemical	MESH:C040548
8064804	1405	1408	rat	Species	10116
8064804	1457	1466	propargyl	Chemical	-
8064804	1479	1481	7d	Chemical	-
8064804	1620	1636	propargyl esters	Chemical	-
8064804	1640	1668	1,4,5,6-tetrahydropyrimidine	Chemical	-
8064804	1673	1707	2-amino-3,4,5,6-tetrahydropyridine	Chemical	-
8064804	1800	1806	(R)-4a	Chemical	-
8064804	1812	1814	7a	Chemical	MESH:C040548
8064804	1838	1840	4d	Chemical	-
8064804	1846	1848	7d	Chemical	-
8064804	1888	1893	ester	Chemical	MESH:D004952
8064804	1989	1995	(R)-4a	Chemical	-
8064804	2000	2002	7a	Chemical	MESH:C040548
8064804	2197	2205	ammonium	Chemical	MESH:D064751
8064804	2215	2228	acetylcholine	Chemical	MESH:D000109
8064804	2374	2382	patients	Species	9606
8064804	2388	2407	Alzheimer's disease	Disease	MESH:D000544
8064804	Association	MESH:D000109	MESH:D000544
8064804	Association	MESH:D064751	MESH:D000544
8064804	Association	MESH:D000109	MESH:D004952
8064804	Association	MESH:D000109	MESH:D064751
8064804	Association	MESH:D004952	MESH:D064751
8064804	Association	MESH:D004952	MESH:D000544

